These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22232131)

  • 1. Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.
    Mikolajczyk RT; Horn J; Damm O; Kaufmann AM; Kretzschmar ME
    J Natl Cancer Inst; 2012 Jan; 104(2):163; author reply 163-4. PubMed ID: 22232131
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
    Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A;
    J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
    Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
    Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
    Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
    Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
    Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
    Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.
    Introcaso CE; Dunne EF; Hariri S; Panicker G; Unger ER; Markowitz LE
    Sex Transm Infect; 2014 Sep; 90(6):505-8. PubMed ID: 24748563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Serological Epidemiological Survey of Antibodies against 4 HPV Subtypes in Uygur Women in Xinjiang.
    Husaiyin S; Han L; Mamat H; Husaiyin K; Wang L; Niyazi M
    Jpn J Infect Dis; 2016 Jul; 69(4):273-8. PubMed ID: 26255734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
    Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
    Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV vaccination: for women of all ages?
    Castle PE; Schmeler KM
    Lancet; 2014 Dec; 384(9961):2178-80. PubMed ID: 25189357
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
    Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
    J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
    Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children.
    Marais DJ; Sampson CC; Urban MI; Sitas F; Wiliamson AL
    J Med Virol; 2007 Sep; 79(9):1370-4. PubMed ID: 17607783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of human papillomavirus 16 and 18 neutralizing antibodies in prenatal women in British Columbia.
    Krajden M; Karunakaran K; So S; Palefsky JM; Sharma R; Cook D; Yu A; Chow R; Dobson S; Ogilvie GS; Petric M
    Clin Vaccine Immunol; 2009 Dec; 16(12):1840-3. PubMed ID: 19828766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
    Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
    Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis.
    Beachler DC; Jenkins G; Safaeian M; Kreimer AR; Wentzensen N
    J Infect Dis; 2016 May; 213(9):1444-54. PubMed ID: 26690341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report.
    Siddiqui MA; Perry CM
    BioDrugs; 2006; 20(5):313-6. PubMed ID: 17025377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.